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Abstract  
Objectives: To explore alignment of experiences before lymphoma and myeloma diagnosis with the 
appraisal, help-seeking and diagnostic intervals in the Model of Pathways to Treatment (MPT). 
Design: A qualitative study using in-depth semi-structured interviews with patients and relatives. 
Interviews were transcribed verbatim, anonymised and analysed using qualitative description.  
Setting: A UK population-based haematological malignancy patient-cohort.  
Participants: Fifty-five patients (35 lymphoma, 20 myeloma: diagnosed 2014-2016) and 28 relatives 
participated, within around a year of the patient’s diagnosis. Patients were selected from those in 
the cohort who had returned a questionnaire about their symptoms and help-seeking, and 
consented to contact for further research. Sampling was purposive, to achieve maximum variation in 
age, sex and time-to-diagnosis. 
Results: Participants described time from symptom-onset to diagnosis as ranging from several weeks 
to years. Pathways largely aligned with MPT components and help-seeking could lead to the rapid 
investigations and identification of abnormalities. However, symptoms could be vague and/or 
inadvertently interpreted as other conditions, which if perpetuated, could cause diagnostic delay. 
The latter was associated with chaotic pathways, with activities rarely occurring only once or in a 
linear sequence. Rather, intermittent or ongoing processes were described, moving forward and 
backwards through intervals. This is ‘unpacked’ within five themes: 1) appraisal and re-appraisal; 2) 
patient-initiated self-management/treatment; 3) initial help-seeking; 4) re-presentation; and 5) 
patient-initiated actions, decisions and emotions during re-presentation. Within these themes, 
various healthcare professionals were consulted, often many times, as symptoms 
persisted/progressed. Input from family/friends was described as substantial, as was the extent to 
which information seeking occurred.  
Conclusion: Lymphoma and myeloma pathways align with the MPT, but do not fully capture the 
repetition and complexity described. Time-to-diagnosis was often prolonged, despite best efforts of 
patients, relatives and healthcare professionals. The impact of NHS England’s Multi-diagnostic 
Disciplinary Centres on time-to-diagnosis remains to be seen.  
 
Strengths and limitations of this study  
• In-depth interviews generated detailed data about complex experiences before diagnosis. 
• The views of patients and relatives are captured, within contemporary healthcare systems. 
• Maximum variation sampling ensured findings are largely transferable to similar settings.  
• Patients were interviewed within a year of diagnosis and asked to use diaries to promote recall. 
• As the sample was derived from individuals returning a questionnaire about their symptoms and 
help-seeking, the views of people unable to do this are not captured.  
 
Keywords: Myeloma, lymphoma, diagnostic delay, help-seeking, patient pathways, qualitative 
research 
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1.0 Introduction  
Early diagnosis of symptomatic cancer can lead to improved quality of life and survival1,2, and has 
been a long-term UK policy priority, promoted via GP referral guidelines and waiting-time targets3–5. 
The impact of such measures has been variable, however, with substantial reductions in time-to-
diagnosis seen for some cancers, but limited benefits for others; and some actually seeing 
increases6. Further targets and initiatives introduced in the recent NHS Long Term Plan7, as well as a 
broader range of potential pathways to diagnosis8,9, confirm this as an area that continues to be 
clinically relevant, with early diagnosis still considered key to improving UK cancer survival.  
Arising in blood and lymph forming tissues, haematological malignancies (leukaemia, lymphoma and 
myeloma) are collectively the fourth most common cancer among men (after prostate, lung and 
bowel) and women (after breast, lung and bowel) in economically developed regions of the world10–
13. With diverse pathways and treatments, the World Health Organization currently recognizes over 
100 heterogeneous haematological malignancy subtypes, which display a range of behaviours and 
outcomes14. Myeloma, for example, generally presents in the bones and often requires intermittent 
treatment throughout a remitting-relapsing pathway, that is more typical of chronic disease than 
cancer. Non-Hodgkin lymphoma and Hodgkin lymphoma each have further subtypes, arise in various 
nodal/extra-nodal site(s) and may be indolent or aggressive. Myeloma and indolent lymphomas (e.g. 
follicular lymphoma) are considered incurable at diagnosis, but can often be controlled for long 
periods of time. Aggressive lymphomas (e.g. diffuse large B-cell lymphomas) are potentially curable 
with chemotherapy, but many patients still die from these diseases.  
Patterns of disease onset and time-to-diagnosis of lymphoma and myeloma are varied. For example, 
patients may be asymptomatic and diagnosed incidentally or they may have multiple and/or severe 
symptoms, that can be diverse and similar to other self-limiting conditions (e.g. fatigue, bone pain, 
swollen glands) to which they are often initially attributed or ‘normalised’; symptoms may also be 
vague and non-specific in onset or intermittent15–17. Importantly, time-to-diagnosis can be prolonged 
and associated with multiple GP consultations before hospital referral18–23, myeloma being one of 
very few cancers that has seen increases in time-to-diagnosis in recent years, despite policy 
initiatives6. Emergency presentation is comparatively common in these cancers, a route linked to 
advanced disease, more complications and poorer survival than other pathways24–26. Conversely, 
fewer two-week wait referrals are made to secondary care and more routine GP referrals than for 
other malignancies, suggesting cancer is not suspected at the time of hospital referral.  
In the UK, a contemporary schematic template (known as the Model of Pathways to Treatment: 
MPT, Figure 1)27 is recommended for mapping and examining pathways to cancer diagnosis, along 
with a checklist to ensure consistent definitions, terminology, methods, data collection and 
reporting between studies28. The MPT comprises a series of intervals beginning with appraisal 
(patient appraisal of symptoms and self-management); followed by help-seeking (decision to consult 
a healthcare professional (HCP), and make and attend an appointment); the diagnostic interval (HCP 
appraisal, investigation, and referral); and the pre-treatment interval (diagnosis to the start of 
treatment). Each interval is impacted by contributing factors, including patient actions, healthcare 
systems and disease characteristics. The MPT authors acknowledge that the intervals they describe 
may require ‘unpacking’ by cancer-type27. The overarching aim of the current paper is to address this 
by ‘unpacking’ the MPT, based on the experiences described by patients with lymphoma and 
myeloma and their relatives, in the time leading to diagnosis.  
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2.0 Methods  
Given the difficulties described above in achieving lymphoma and myeloma diagnosis, a mixed 
methods study was set-up to explore the experiences of patients (and relatives) before diagnosis, 
which has, to date, resulted in several publications using data from medical records and qualitative 
interviews16,17,25. The current paper is based on the qualitative study phase, the methods of which 
are outlined below in accordance with the consolidated criteria for reporting qualitative studies 
(COREQ)29. Qualitative data are known to be well suited to investigating how people make sense of 
their situation, and how and why they make particular decisions30. In this study, our theoretical 
approach adhered to the principles of qualitative description31,32, an applied method facilitating the 
production of concrete, low inference descriptions with practical relevance. The MPT27 was used as a 
framework from which to examine activities within the appraisal, help-seeking and diagnostic 
intervals, as this is where the most significant delays are considered to occur17. 
The qualitative study examining diagnostic pathways was based within the UK’s Haematological 
Malignancy Research Network (HMRN: www.hmrn.org), detailed methods of which have been 
published elsewhere33,34. Briefly, HMRN is a specialist population-based cohort which was initiated in 
2004. It tracks entire treatment pathways and collects data on all patients newly diagnosed with 
haematological malignancies across 14 hospitals (catchment population ~4 million) in the North of 
England (Yorkshire and Humberside). In addition to clinical data collection, HMRN patients are 
routinely asked to complete a questionnaire about their symptoms and help-seeking.  
Potential interviewees for the qualitative study were derived from patients completing the routine 
questionnaire in the HMRN area, who were aged ≥18 years, and within around 12 months of 
diagnosis. Sampling was purposive and designed to achieve maximum variation in age, sex and time-
to-diagnosis. Ninety-two people were posted study material and invited to contact the research 
team if they wanted to participate; they were also invited to ask a relative/carer to contribute to the 
interview if they wished. Fifty-five patients (diagnosed 2014-2016; 20 with myeloma; 35 with 
lymphoma) and 28 relatives were interviewed, with data collection continuing until saturation. An 
overview of patient characteristics and the duration of intervals can be found in Table 1, with further 
information provided in the Supplementary Table, S1.  
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Table 1 Overview of participant characteristics (n=55) 
Diagnosis Patients 
(Relatives1) 
Total 
females 
Total 
males 
Median age 
Years (range) 
Duration of intervals  (months/range) 
Appraisal/help-seeking2 Diagnostic3 Total3  
Non-Hodgkin lymphoma4         
• Diffuse large B-cell 12 (7) 5 7 64 (48-81) 0.5-13 1-15 2-17 
• Follicular lymphoma 9 (3) 4 5 63 (39-84) 0.5-12 1.5-12 2-15 
• Marginal zone  6 (1) 4 2 62 (57-76) 0.5-11 3-25 3.5-25.5 
• Mantle cell 3 (3) 2 1 71 (70-75) 1-6 2-10 2.5-10.5 
        
Hodgkin lymphoma4 5 (2) 2 3 36 (23-56) 0.5-12 1-12 3.5-13 
        
Myeloma4 20 (12) 14 6 68 (43-78) 0.5-7 0.5-17 2-18 
        
Total 55 (28) 31 24 64 (23-84) 0.5-13 0.5-25 2-25.5 
1Spouses, partners, children; 2Initial symptom/health change to first help-seeking (from information estimated by patients completing the routine self-reported HMRN 
questionnaire). 3First help-seeking to diagnosis (start point also estimated from the self-reported HMRN questionnaire); 3Initial symptom/health change to diagnosis. 
 
 
 6 
 
Interviews (conducted November 2015-May 2016 by RH and DH, both of whom were previously 
unknown to participants), were semi-structured and guided by a schedule, developed from existing 
literature, as well as clinical advice from within the study team (Table 2). With written consent, 
patients were asked to describe their pathways from first symptom(s) or health change(s) to 
diagnosis. Most interviews were carried out face-to-face in the patients home, although several 
were conducted in hospital or university settings, and a minority occurred by telephone. Interviews 
lasted around 45 minutes and were audio-recorded, transcribed, anonymised and checked, with 
field-notes used to confirm accuracy and support data analysis. 
 
Table 2 Overview of interview schedule 
Interviewees were asked to describe:  
1. Initial and subsequent symptoms and health changes  
2. Interpretation of symptoms and health changes 
3. Response to symptoms between onset and diagnosis: actions; activities; events  
4. Help-seeking episode(s) and factors influencing this  
5. Where, when and with whom help-seeking occurred  
6. Management by healthcare professionals (primary/secondary care) 
 
Analysis was iterative, running alongside and informing data collection (RH, DH). After review and 
familiarisation with transcripts, narrative summaries were produced from the data and pathways 
were mapped-out visually and shared with the research team (ER, AS). Several rounds of coding 
were undertaken, focusing on different aspects of the data, including activities and events occurring 
within intervals defined in the MPT. Constant comparison (codes with codes, codes with data, codes 
with theory) and memo-ing35 supported refinement of codes and identification of patterns and 
relationships. Codes and emerging themes were discussed by the team and refined until consensus 
was reached. Input from relatives was analysed alongside that of the patient, using the same 
methods. 
Patient and Public Involvement (PPI) 
PPI is integral within HMRN, and takes place via a dedicated Partnership, overseen by a lay-
committee. Patients from the Partnership were involved in identifying the research questions 
underpinning the study during several focus group meetings, where they highlighted the difficulties 
they had experienced getting diagnosed; they were also involved in study design via our funding 
application. Furthermore, patients routinely assist in the dissemination of all HMRN findings, which 
also occurs via our lay-website: www.yhhn.org. 
3.0 Findings 
Participants described time from symptom-onset to diagnosis as ranging from several weeks to 
numerous years. Within this disparate time-frame, pathways largely aligned with MPT, although 
experiences were more chaotic and did not always fit this model’s distinct intervals or linear 
trajectory. This is ‘unpacked’ within five themes: 1) appraisal and re-appraisal; 2) patient-initiated 
self-management/treatment; 3) initial help-seeking; 4) re-presentation; and 5) patient-initiated 
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actions, decisions and emotions during re-presentation. Each theme is described below using 
illustrative verbatim quotes and summarised in Figure 2.  
3.1 Appraisal and re-appraisal 
Patient appraisal of symptoms and health changes was described as ongoing by participants, with 
observation and monitoring occurring periodically or continuously from first symptom to diagnosis. 
When ‘normal’ health was not regained, appraisal was said to become more deliberate and rigorous. 
It involved, for example, checking and comparing affected and non-affected sites: ‘My mind was 
going, “If you can feel (a lump)...  sides, then it’s normal. If you can feel it on one side, then that’s 
something to worry about”. So I tried, I felt the other side, and again…’ [Lymphoma patient 06: L06]. 
This was said to take place repeatedly over time: ‘I couldn’t decide whether my skin was a different 
colour…I’d look at it and think, “It looks strange”, and then I’d look again, and it didn’t’ [L03].  
Interviewees described re-appraising persistent, progressive or new symptoms, which could be 
perceived to be related, or unrelated, to the initial problem. Unremitting symptoms sometimes led 
to more precise and formal appraisal, including documentation of health changes, pain, medication 
and weight: ‘I kept a note, like week-by-week almost’…[L25]. A key element of appraisal involved 
patients and relatives considering numerous explanations for their symptoms over time. This 
included ‘normalisation’ of symptoms by attributing these to life-course issues (e.g. age or  
menopause related) or events (decorating), or self-limiting conditions: ‘Could I have ME?’ [L05]; 
‘Maybe it was an ulcer’ [L26]; ‘I was just thinking, “actually, is this becoming a mental health issue? Is 
it (the) first signs of dementia?”’ [Relative of myeloma patient 20: M20].   
Interviewees described information seeking from various sources during appraisal/re-appraisal, 
particularly for ongoing symptoms; an issue not wholly acknowledged in the MPT. One myeloma 
patient consulted relatives about their family history (osteoporosis) as a potential explanation for 
symptoms. Others described questioning medically experienced friends, colleagues or 
acquaintances: ‘There’s a doctor…lives further down the lane…I said [to him] “I don’t really like 
asking but…”’ [L03]. Many explored symptoms via the internet: ‘I’d looked at all sorts of problems I 
thought (patient) might be having with bones”’ [Relative, M20]. Internet searching was more 
effective when symptoms were typical of myeloma or lymphoma: ‘I think I put in something like 
“itchy skin, night sweats, lump in neck”; Hodgkin’s lymphoma came up, through a few different 
clicks’ [L14]. This could lead to rapid help-seeking/re-presentation: ‘had I not seen (information), I’m 
not convinced I would have said anything to the doctor, but because I’d seen it and I thought, “Crying 
out loud…”, I was like, “We’ve got to do something…someone needs to put all these pieces of the 
puzzle together”’ [Wife, L14]. It could also lead to emergency presentation: ‘the more I read (about 
lump), the more I was scared, and I just went to A&E…”’ [L23]; or denial: ‘Well, when I started 
reading about cancer I just switched it off, because I thought, “No, no, that’s not right”’ [L05].  
Considerable involvement of relatives, friends and colleagues in appraisal/re-appraisal was 
described, though not wholly depicted in the MPT: I just looked at his tummy and I thought, “that’s 
an odd shape, that”, and it just flashed through my mind and I thought “That could be a tumour”’ 
[Relative: L20]. Some relatives said they adapted their own behaviour to accord with the patient, 
often over long time-periods: ‘(Patient’s) height loss, was gradual, at first, so, I noticed…I stopped 
buying shoes with heels, because I was getting to be, you know, too tall (for him) when I was wearing 
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shoes with heels…That had probably been going on…maybe a couple of years’ [Relative: M18]; or 
they began to discuss the patient’s symptoms and health changes between themselves: ‘We knew 
there was something wrong…my daughter actually said, “You know, dad’s not right at all, is he?”’ 
[Relative: M02].  
3.2 Patient initiated self-management/treatment 
Self-management was not solely associated with the appraisal interval as portrayed in the MPT, but 
was described as occurring throughout the pathway, particularly if patients or HCPs had normalised 
initial symptoms to self-limiting or life-course issues (e.g. age, menopause): ‘we’re the kind of people 
who go to the doctor as a last resort, and we’d tried the obvious things ourselves, you know (lists 
remedies for indigestion), anything you think might ease it. But it didn’t…’ [Relative: L20].  
Some patients said they used distraction techniques for relief, often long-term: ‘I wake up because 
my tummy’s hurting, and then I get up and start the day, and then I try and fill my day with things, so 
that I don’t think about it…and, that was how it went and, we’re probably talking a couple of years of 
that…just putting up with these different things’ [L26]. Others reduced or stopped activities viewed 
to cause/aggravate problems: ‘You’d stopped driving for about two months (before diagnosis), 
because you were in…pain’ [Relative: M03]; [Interviewer: ‘You gave up work 18 months ago…?’] 
‘Yeah…it were getting a little bit difficult for me, and I didn’t want to embarrass myself’ [L16].  
People described using aids over long time-periods: ‘I used to go to work with that belt (meant for 
weight-lifting), you know, on my back’ [M15]. Others used sticks, wheelchairs or riser-chairs to 
remain mobile. Lifestyle changes were made: ‘I’ve had grumbling problems… probably at least two 
years…the kind…you treat yourself, with indigestion medicine, drinking water, trying to eat well, 
going for exercise, all those things that you think “This’ll sort me out. I’m just getting a bit older and I 
need to look after myself” [L26]. Some took supplements ‘we were having Complan drinks with 
whole milk…protein drinks, powders, anything to get something into his system…the weight back’ 
[Relative: L20]; or self-medicated with analgesics, anti-inflammatories, anti-histamines and gargles.  
Long-term strategies were reported to manage debilitating tiredness, including napping or sleeping 
more: ‘I were feeling tired all the time…I used to eat my sandwiches before my lunch…as I went 
round, and then as I stopped the van, I used to turn the ignition off, and lay on the seat, and go to 
sleep’ [L16]; ‘I tended to sleep a lot. I’d come home for lunch at 12 o’clock…fall asleep in the chair… 
almost every day…’ [M12]. And then you’d come home and fall asleep, and you’d wake up and have 
tea, then fall asleep again, and then wake up for a couple of hours watching telly, and then go to 
bed’ [Relative: M12].  
Some people said they chose to pay for specific treatments, with mixed results: ‘(physiotherapy) 
made matters worse’ [M18]; ‘eventually, he were in that much pain, he couldn’t go... (to 
physiotherapy)’ [Wife: M15]; ‘I went to an osteopath…which did help’ [M12]; An ‘herbalist’ and an 
‘allergist’ were also consulted; and one person considered ‘colonic irrigation’.  
3.3 Initial help-seeking  
Concurring with the MPT, all patients described help-seeking for symptoms and attended their GP at 
some point. The decision to seek help and the timing of this event was often said to be influenced by 
relatives, friends or colleagues, who could encourage help-seeking: ‘My mum and friends (were) 
saying, “You…really ought to go to the doctors”’ [M05]; or indeed discourage it: ‘I had these lumps 
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on my neck and I, I didn’t take any notice of them…I said to a friend and she said…“Oh it’s nothing, 
everybody gets lumps”’ [L15]. 
A minority said initial help-seeking led to the rapid identification of abnormality/suspected cancer, 
which was quickly investigated and diagnosed: ‘The doctor…was lovely and she examined 
(patient)…and said “I can feel something, in there, and she booked him in…for a CT scan…endoscopy, 
yeah, and a blood test…on the scan they saw, there was a mass’ [Relative: L20]; ‘(GP) did a very 
thorough check…he’s always been very thorough...physical and, yeah, mental if you like…I’ve always 
found him absolutely superb. (He) listens not just to what you say, but what you don’t say and, and 
sort of, reads the signals; [L01]; (GP) decided it was something serious, and then you were sent for a 
scan…you had a biopsy, and it all happened very quickly’ [Relative: L01].  
Initial help-seeking could include requests for broad health-checks: ‘I just felt, okay I’ll go to the 
doctor’s and…(say), “Well, I want an MOT…I seem a bit tired”…and it was a locum, and I explained 
my symptoms, and he sort of said, “Well, they seem a bit of an odd set of symptoms, so we’ll give 
you…full blood tests”, and thank goodness he did’ [M05]; ‘I did sort of ask for like a ‘well woman’ 
check, because I didn’t in my mind feel like I was right’ [L17]. General interventions were also sought: 
‘I was just really feeling fed up, because I was so tired…I went for a tonic, I said, “Can you give me 
just something to pick me up?”’ [L34]. Alternatively, other conditions were initially suspected, 
particularly if these conditions had symptoms that were also associated with myeloma or lymphoma: 
‘I noticed a swelling at the top of my groin…(GP) said “that feels like a, a hernia to me…I’ll sort you 
out an appointment to get you referred”’ [L06].  
3.4 Re-presentation 
As initial help-seeking only rarely led to diagnosis, re-presentation was extremely common. This was 
said to occur quickly with increasingly alarming symptoms: ‘(I) went to the bank, and wet myself… 
and I thought, “Oh my God… what’s going on here?” And I went (back) to the GP’ [L09]; ‘the 
sickness…he started bringing his evening meal up, and unable to sleep at night, the pressure on his 
tummy…he’d be walking the floor, you know, just generally, obviously something very wrong [L20].’ 
It could be delayed if the patient was told resolution may take time: I saw two (GPs)… [Interviewer: 
Who said?] ‘Give it time’ [M13]; or if symptoms were intermittent: ‘he’d be ok for a while, and then, 
you know, maybe a few nights he’d be sick’ [Relative: L20]; ‘I carried on working, as you do…I didn’t 
feel too bad really, some of the time’ [L20]. 
Alternatively, repeat GP consultations could be delayed, particularly if initial/differential diagnoses 
were perpetuated: ‘I noticed, like, a little pea-sized lump in my leg…my right calf…I thought… 
“Probably me varicose veins”. I didn’t rush, I went to see the doctor, regarding something else, and I 
just happened to mention to him about it… he had a feel of it, and he says “right, we’ll send you off 
to have and ultrasound”, you know, get it checked out. I asked (radiographer)…“Is it a varicose vein?” 
She says “yes”. ‘I got on with my life, I just carried on. I thought well fair enough, you know, its 
varicose veins…I never bothered when I started getting other lumps in my leg, I thought, “well it’s all 
just part of it”. (The following year) this lump was steadily growing…I started getting other 
lumps…the lumps joined together…starting to turn red and poke out of my skin...It just sort of 
exploded sort of thing, you know, it was frightening how fast it was growing…I went to see the 
doctor again’ [L31]. 
Re-presentation often occurred on multiple occasions: ‘I went back probably about three times 
between February and August… [M13]; ‘all that time, just going backwards and forwards to the 
doctors’ [Relative: L24]. Sometimes this was associated with ongoing normal investigations: ‘I just 
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felt so tired. I’d just no energy, you know, and the daft part is, I think I’d three lots of blood tests done 
as well, to try and find out, you know, and yet none of ‘em showed anything to do with the 
lymphoma’ [L31]; ‘The blood test revealed nothing, did it, and neither did the camera in the stomach’ 
[L20]. Where abnormal blood tests were noted, rapid hospital referral was described: ‘I’d had about 
four or five different blood tests, and it were all coming back negative’ [M15]…‘til these blood tests 
did come back abnormal, all of a sudden, so that’s when they sent him up to haematology [Relative: 
M15]; ‘(GP) immediately, more or less said, I’m sending you into hospital. You’re anaemic’ [L24]. 
Repeat consultations sometimes occurred at the request of HCPs: ‘(GP) said to me if there are ever 
any changes with the lumps to inform him’ [M12]. This was sometimes associated with HCPs 
expressing frustration about their inability to explain symptoms: ‘(GP) said: “come back in four 
weeks…I’m getting me books out…I don’t understand what the symptoms are pointing me to” [L24, 
paraphrasing GP]. Interestingly, this patient’s main concern (‘night urination…combined with the loss 
of weight, that was what really got me, erm, worried’), remained unresolved after successful 
treatment, and at this point was considered unrelated, with urology review awaited.  
Re-presentation also occurred due to a growing conviction something was really wrong: ‘Normally 
I’m not somebody who goes to (the) doctors…it was just a feeling that something definitely wasn’t 
right. Despite getting the first opinion’ [L01]; My mobility was shocking by then…I was having great 
difficulty in doing anything, literally and I knew then that there was something…’ [M03]; ‘I weren’t 
going to take “no” for an answer… because I knew there was something’ [L34]. Doubt about an 
earlier explanation was often key: ‘I was convinced there was something wrong with me, other than 
osteoporosis, because I thought “I shouldn’t feel, this unwell, with osteoporosis.”’ [M14].  
HCPs directed a number of patients towards emergency (re)presentation, either via A&E or a direct 
ward admission, often for worsening symptoms and to gain rapid access to healthcare. ‘I saw the 
nurse, and she said, “Look, you know, go to A&E and let them have a look at it, so that’s what we did’ 
[L31]. Symptom complexity could result in consultation with multiple specialists even via this route, 
with the same patient being assessed by the A&E team, then a physiotherapist, vascular surgeon and 
plastic surgeon, before being told “it’s a tumour” [L31].  
3.5 Patient-initiated actions, decisions and emotions during re-presentation 
Some interviewees described requesting more specific input from their HCP at re-presentation, 
including direct appraisal: ‘you need to see my neck again’ [L14]; ‘have a look while I’m standing up’ 
[L34]; ‘I said to (GP)…“Can you actually measure me?” which she did…she indicated… that I’d lost 
about two inches’ [M14]; and particular investigations: ‘I said, “Look, there’s something wrong here. I 
need an X-ray”’ [M13]; ‘I said “I’m not picking up” and she agreed (to blood tests)’ [L05]. 
Evidence (e.g. diaries) was often produced by patients at re-presentation to demonstrate the extent 
and severity of symptoms: I thought, “(GP’s) probably thinking I’m just a hypochondriac”. But when I 
got the evidence of the weight that I was losing, I didn’t feel that…(GP) could turn a blind eye to that.’ 
[L25]. New information from re-appraisal (symptoms, mismatch between symptoms and preliminary 
diagnoses, and test results) or internet searching was also said to be passed on to HCPs: ‘I said, “I 
think I’ve got lymphoma…I seem to have these lumps that haven’t gone down at all…and I think now 
I’m getting, it’s either anxiety, or I’m now getting B-symptoms, which is night sweats…”’ [L06]. This 
could prompt action: ‘I went back to the GP and said, “Well, (ENT) say it’s TB or lymphoma”, and the 
GP said, “Well, I don’t think it’s lymphoma, but, if they’re saying TB, I’ll send you for an X-ray”’ [L07]; 
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but not always: ‘I’d been in pain for a long time, and I actually said, “I think I’ve got cancer” and (Dr) 
said to me, “You don’t look like somebody who’s got cancer”’ [M14]; ‘(GP) said, “No, no, you 
haven’t…lymphoma, old people get lymphoma. You’re (under 40)…don’t even think about that”’ 
[L06]. Patients reported chasing-up information to give to HCPs (e.g. results): ‘I rang (surgery), three 
times a week, every week, to see if they’d had a reply’ [Relative: L11].  
Others blamed themselves for their delayed diagnosis, saying they only gave HCPs partial 
information about their symptoms: ‘maybe I wasn’t forthcoming with the information’ [M03]; either 
purposely (only reporting symptoms they thought the HCP would considered important) or 
inadvertently: ‘I didn’t mention my general apathy, because I just thought it was just apathy to be 
honest’ [M12]; ‘many’s the time I’ve come out thinking, “Oh damn, I didn’t mention that”’ [L24].  
A few patients described feeling obliged to ‘stick with’ the first GP consulted: ‘he knew the situation, 
and I kind of felt like, it’d have been going behind his back to go and see another GP’ [L07]. Others 
did not: ‘The very first doctor I saw. I saw him twice and then I knew after that I wasn’t going to ask 
for that particular doctor’ [M14]. Some reported re-presenting to HCPs they knew and trusted, were 
more experience, or just different: ‘We would sometimes just ask for a different one, just to get a 
different opinion’ [L34]. Decisions were also made to consult various other specialists: ‘I’d started to 
suffer with mouth ulcers, and…I actually went to my dentist’ [L30]; and advice was sought at 
unrelated hospital appointments: ‘I went to see my Crohn’s surgeon… my normal check-up, and I 
mentioned (the lump) to him, and he’s the one really who pushed it forward fast…’ [L32].  
Lack of progress towards diagnosis could lead patients and relatives to ask their HCP to refer/admit 
them to hospital, which could be refused: ‘“Oh no, she doesn’t need to go to hospital”’ [Relative 
paraphrasing HCP, L35]. It also resulted in distress, anxiety and frustration: ‘‘I was getting towards 
my wits’ end, because I knew that there was something wrong, and I just felt as if (HCPs) weren’t 
taking me seriously’ [L06]. Occasionally, this resulted in emotional outbursts: ‘The doctor said, “Have 
some antibiotics”… and we broke down and were just like, “This isn’t right”. So he called the hospital 
and got (Patient) into hospital’ [Relative, L14]; ‘They thought it was anxiety, because I’d got myself in 
a state, and I was in a tearful mess at the doctor’s, because of feeling ill and they’re not getting 
anywhere…So she just thought it was an anxiety issue. It was like turned from one thing to something 
else’ [L17]. 
Patients said their relatives often attended later GP appointments with them to advocate on their 
behalf: ‘you become increasingly dependent on somebody to go with you…for reassurance and 
support’ [M14]; ‘We made and appointment…we had to insist (patient) needed to see someone, and 
we went together, and we said, “we need help here"’ [L20]; ‘“I’m not waiting for this appointment”, I 
said, “because (Husband, the patient) can’t wait”. I said, “I want him to see (haematologist), as soon 
as!” I said, “I know you can do it, because I worked in the health-service” so she said, “Yes, okay”. 
Otherwise, I honestly thought he could sit in the chair and just go (die). He was so ill’ [Relative: L11].  
Some patients and relatives recalled emergency presentation to hospital via A&E, which they 
initiated themselves: ‘I was getting so desperate…I knew something was wrong, and I felt that 
nobody was really listening to what I was saying. I did actually go to A&E a couple of times. Well, 
once under our own steam, and once we rang 111, and they said “Go to A&E”’ [M14]. Several people 
also mentioned eventually seeking private investigations and/or hospital referral, which they 
considered key to diagnosis. Access to private healthcare was said to be rapid: ‘it bought me time’ 
[L13]. Where GPs knew patients had private insurance, they were reported to suggest referral ‘I 
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went backwards and forwards to my GP, and I’m covered by my husband’s private hospital thing, so 
(GP) suggested that I went to see a consultant back specialist’ [L09]. More commonly, patients 
portrayed private care as an extreme but necessary measure: ‘the timeframe for me was…it was too 
much, so I said “I want a private referral”’ [M12]. 
4.0 Discussion  
Principal findings 
Pathways to lymphoma and myeloma diagnosis largely aligned with the MPT27. However, further 
‘unpacking’ confirmed that trajectories were often much more complex and chaotic than depicted in 
the model, with activities rarely described as occurring on a single occasion or in a linear sequence. 
Rather, intermittent or ongoing processes were described, that moved forward through intervals 
(e.g. appraisal to help-seeking), but also back to the start of the pathway, so that repeat/continuous 
re-appraisal occurred, with multiple re-presentations to HCPs, which could cause anxiety and 
distress. Symptoms were ‘normalised’15 and self-management occurred across pathways, not only 
within the appraisal interval. Patients and relatives were also active within the diagnostic interval. 
Input from family and friends was substantial in all intervals, as was the extent to which independent 
information seeking occurred. Disease, patient and HCP factors (as presented in the MPT model), 
were found to influence each part of the pathway, with symptoms and events at one time-point (e.g. 
GP reassurance about symptoms or a normal investigation) influencing later actions and time-scales 
(e.g. delayed patient re-presentation; delayed HCP referral to hospital). Similar experiences were 
reported by patients with myeloma and lymphoma (although more patients with myeloma were 
referred to hospital by the GP after an abnormal blood test); and various HCPs were consulted 
throughout the diagnostic interval. 
Strengths and weaknesses  
This is the only qualitative study exploring pathways to diagnosis of lymphoma and myeloma in the 
context of the MPT, whilst taking an overview that tries to capture the interactions between people 
(patients, relatives and HCPs) and the events/activities taking place throughout the pathway. Our 
study included people diagnosed within contemporary healthcare systems, and after introduction of 
UK referral guidelines, targets and urgent diagnostic routes3–5. The sample is comparatively large (55 
patients; 28 relatives) and in-depth discussions ensured findings were based on personal 
experiences and perceptions. Inclusion of relatives is a unique feature and a particular strength as 
these individuals (spouses, partners and children), were able to contribute their own views of the 
pathway and their involvement in events. Participation from relatives ranged from them taking a 
minor role (for example reminding the patient about dates and events), to having significant input in 
describing the pathway and their own actions and emotions. Interviews were conducted within a 
year of diagnosis and the use of letters, calendars and diaries was encouraged to promote recall. 
Although generalisability is not an overarching aim of qualitative research, maximum sample 
variation increased the transferability36 of findings to places with similar healthcare systems. 
Experiences may, however, differ in countries without universal provision, or where 
secondary/private healthcare gatekeepers are not GPs. Although we believe data saturation was 
reached, our sample was derived from individuals returning the routine HMRN questionnaire about 
symptoms and help-seeking, so did not capture the views of people unable to do this, including 
those dying soon after diagnosis, who may have had more advanced stage disease. Furthermore, 
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although likely to be rare (with hindsight), it is possible that symptoms attributed to myeloma or 
lymphoma by interviewees may in fact be unrelated to their cancer diagnosis.  
Comparison to other studies 
We were unable to identify any other qualitative studies exploring the specific experiences of 
patients with myeloma and only two targeting lymphoma37,38. The latter were both UK-based, and 
also reported descriptions from patients of challenging pathways and difficulties achieving diagnosis. 
Other quantitative work reports multiple GP appointments and delay before diagnosis (particularly 
among myeloma patients); as well as the need to improve time-to-diagnosis18–23. Further studies 
have identified a group of cancers that are ‘harder/difficult to suspect’18,23. Myeloma is amongst this 
group due to its propensity for non-specific symptoms commonly found in the general population 
(e.g. back pain and fatigue19). Other ‘harder to suspect’ malignancies include pancreatic, stomach, 
lung, colon, brain and ovarian cancers, and Hodgkin lymphoma, and also typically have vague and 
intermittent symptoms, as well as complex pathways to diagnosis, including multiple GP 
consultations before hospital referral, more emergency presentations and longer time-to-
diagnosis18,23,39–44. Conversely malignancies with specific signs and symptoms (e.g. breast cancer and 
breast lumps; melanoma and skin lesions), or affecting organs that can easily be examined (e.g. 
testicular or thyroid cancer), generally have fewer GP consultations, more two-week wait referrals 
for suspected cancer, fewer routine referrals and shorter time-to-diagnosis18,23,39,40,43. Given these 
differences, it is highly likely that the latter group will experience the linear compartmentalisation 
depicted in the MPT, whereas the former group are more pre-disposed to the chaotic pathways 
described in this study.  
Meaning of the study and implications for practice 
Our study clearly depicts the complexity of pathways to lymphoma and myeloma diagnosis. It 
clarifies the difficulties experienced in trying to identify the cause of what are often non-specific 
symptoms (intermittent, vague, slowly progressive, common in other illnesses). This occurred often 
despite the best efforts of patients, relatives and HCPs, including patients re-presenting to their GPs 
for reassessment, and GPs requesting numerous investigations, which were often normal (including 
blood tests, imaging and colonoscopy/endoscopy, the latter often initiated due to anaemia). Our 
findings highlight some of the reasons for delays in help-seeking, re-presentation and diagnosis18–22, 
as well as potential explanations for the lack of urgent hospital referrals for suspected cancer and 
the high proportion of emergency presentations17,24–26. Our results also explain why interventions 
such as education campaigns targeting the (very broad) symptoms of these diseases, would probably 
lack impact. Interestingly, some patients reported symptoms that were present before and after 
diagnosis (e.g. nocturia: L24). Whilst such symptoms were considered significant at the time, 
persistence after successful chemotherapy is likely to indicate the issue was unrelated to their 
lymphoma, thus highlighting the difficulty of distinguishing malignant from benign disease. Moving 
forward, and in the absence of clear symptom signatures and blood tests45–47 (although certain tests 
can rule myeloma in or out48), it is important that the complexity experienced by patients with 
myeloma and lymphoma, as well as other ‘harder to suspect’ cancers, is acknowledged within 
strategies to reduce time-to-diagnosis, including those set out in the NHS Long Term Plan7. 
Importantly, this document introduced Rapid Diagnostic Centres (RDCs) that provides GPs with an 
alternative fast access pathway to secondary care for patients with symptoms that are worrying, but 
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non-specific, so do not suggest referral to a specific speciality. This could represent a significant 
change in the context of myeloma and lymphoma, as well as other ‘harder to suspect’ cancers, 
particularly if used in conjunction with rigorous safety netting in primary care4,49, of which some 
evidence was found in the current study. For members of the public, individual recognition of their 
own ‘normal’ is key, as well as having the confidence to pursue help-seeking for unexplained 
symptoms.  
Unanswered questions and future research  
Primary care HCPs have significant input into the care of patients later diagnosed with cancer, 
including those with emergency presentation50. To our knowledge, however, there have been no 
qualitative studies exploring GP experiences of managing patients with lymphoma or myeloma. Nor 
is there any work linking primary and secondary healthcare data, although such studies would clarify 
the occurrence and timing of events between symptom onset and diagnosis and promote 
understanding of these complex pathways. Exploring the impact of RDCs on time-to-diagnosis and 
disease stage at diagnosis will provide insights into the efficacy of this new pathway for patients with 
myeloma and lymphoma.  
 
Figure 1 Model of Pathways to Treatment27 
 
Figure 2: Summary of key themes and components 
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Figure 1 The Model of Pathways to Treatment27 
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Figure 2 Summary of key themes and components 
Theme 1: Appraisal and re-appraisal   
• Ongoing (intermittent or continuous), from symptom onset to diagnosis  
• Became more precise and formal over time (use of diaries to document changes etc.)  
• Various other explanations for symptoms considered (‘normalisation’, self-limiting conditions)  
• Information sought independently (internet, relatives, friends, colleagues etc.)  
• Relatives were involved and adapted their behaviour to the patient’s symptoms  
  
Theme 2: Patient initiated self-management/treatment  
• Ongoing (intermittent or continuous), from symptom onset to diagnosis  
• Coping mechanisms (distraction techniques, use of aids such as sticks, wheelchairs)  
• Physical adaptation (stopping work, driving, hobbies)  
• Lifestyle changes (healthy diet, exercise)    
• Paying for treatments (over the counter medication, physiotherapy, osteopath)  
  
Theme 3: Initial help-seeking   
• All patients sought help from healthcare professionals (HCPs)  
• Impacted by advice from relatives, friends, colleagues etc.   
• Broad health checks and general interventions requested  
• Could lead to identification of abnormality/suspected cancer and rapid investigation  
• Various other explanations for symptoms considered (‘normalisation’, self-limiting conditions)  
  
Theme 4: Re-presentation   
• Common   
• Could occur on numerous occasions  
• Response to:   
o worsening, progressive, new or alarming symptoms 
o inability to perform ‘normal’ activities 
o a growing feeling ‘something’ was wrong, but not knowing exactly what 
o lack of progress towards diagnosis  
• Associated with negative investigations (blood tests, radiology, endoscopy, colonoscopy)     
• Follow-up could be requested by the HCP (safety netting)  
• Dependent on initial advice/diagnosis given to patient by HCP  
• Seek advice from various HCPs (dentists, physiotherapists, complementary therapists)  
• Emergency route (sent to A&E by HCP, NHS helpline etc.)  
  
Theme 5: Patient initiated actions, decisions and emotions during re-presentation   
• Requested more specific help (appraisal of specific sites, particular investigations)    
• Evidence presented to show symptom severity/persistence (diary, internet material)  
• Giving GPs just the information the patient thought they would consider important   
• Attend the same, a different or a specifically identified GP  
• Hospital referral/admission requested    
• Emotional outbursts  
• Involvement of relatives/others to advocate on behalf of the patient  
• Use of Emergency route (self-referral to A&E instigated by patient)  
• Use of private healthcare to access specialist assessment  
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Supplementary Table S1: Patient identification, diagnosis, sex, age, time to diagnosis (estimated) 
and relative’s involvement 
Patient ID Diagnosis Gender Age1  
(Years) 
Time to diagnosis (months) Relative took part 
in interview (Y/N) T12 T23 T34 
L015 Follicular lymphoma M 66 1 1.5 2.5 Y 
L02 Diffuse large B-cell lymphoma F 48 1 2 3 N 
L03 Follicular lymphoma F 63 1 3 4 N 
L04 Diffuse large B-cell lymphoma F 64 1.5 1.5 3 N 
L05 Marginal zone lymphoma F 57 0.5 3 3.5 N 
L06 Follicular lymphoma M 39 2 6.5 8.5 N 
L07 Classical Hodgkin lymphoma F 36 0.5 12 12.5 N 
L08 Diffuse large B-cell lymphoma M 60 13 2 15 Y 
L09 Diffuse large B-cell lymphoma F 62 0.5 6 6.5 N 
L10 Follicular lymphoma M 80 0.5 10 10.5 Y 
L11 Mantle cell lymphoma M 71 0.5 10 10.5 Y 
L12 Follicular lymphoma F 84 0.5 1.5 2 R 
L13 Follicular lymphoma M 63 12 3 15 N 
L14 Classical Hodgkin lymphoma M 33 0.5 4 4.5 Y 
L15 Mantle cell lymphoma F 75 6 2 8 Y 
L16 Marginal zone lymphoma M 64 9 5 14 N 
L17 Classical Hodgkin lymphoma F 37 12 1 13 N 
L18 Follicular lymphoma M 53 1 12 13 N 
L19 Classical Hodgkin lymphoma M 56 2 5 7 Y 
L20 Diffuse large B-cell lymphoma M 64 1 5 6 Y 
L21 Diffuse large B-cell lymphoma F 81 0.5 6 6.5 N 
L22 Follicular lymphoma F 52 0.5 2 2.5 N 
L23 Classical Hodgkin lymphoma M 23 0.5 3 3.5 N 
L24 Diffuse large B-cell lymphoma M 75 1 10 11 Y 
L25 Marginal zone lymphoma F 76 0.5 20 20.5 N 
L26 Follicular lymphoma F 63 8 6 14 N 
L27 Diffuse large B-cell lymphoma M 64 1 1 2 Y 
L28 Marginal zone lymphoma F 76 11 3 14 Y 
L29 Diffuse large B-cell lymphoma M 60 0.5 1.5 2 Y 
L30 Marginal zone lymphoma M 60 0.5 25 25.5 N 
L31 Diffuse large B-cell lymphoma M 65 2 15 17 N 
L32 Diffuse large B-cell lymphoma M 64 0.5 3 3.5 Y 
L33 Marginal zone lymphoma F 60 1 14 15 Y 
L34 Mantle cell lymphoma F 70 0.5 2 2.5 N 
L35 Diffuse large B-cell lymphoma F 69 8 1 9 Y 
Myeloma 016 Myeloma M 67 1 2.5 3.5 Y 
M02 Myeloma M 63 2.5 7 9.5 Y 
M03 Myeloma M 71 1 17 18 Y 
M04 Myeloma F 78 1 5 6 N 
M05 Myeloma F 55 1 4 5 N 
M06 Myeloma F 71 3 1.5 2.5 Y 
M07 Myeloma F 56 1 8 11 N 
M08 Myeloma M 68 1 3 4 Y 
M09 Myeloma M 70 1 2 3 N 
M10 Myeloma M 74 2 0.5 2.5 Y 
M11 Myeloma M 59 3 15 18 N 
M12 Myeloma M 43 3 8 11 Y 
M13 Myeloma M 71 1 7 8 N 
M14 Myeloma F 59 1 8 9 Y 
M15 Myeloma M 58 1 17 18 Y 
M16 Myeloma M 66 3 15 18 N 
M17 Myeloma M 70 0.5 2 2.5 N 
M18 Myeloma M 71 1 11 12 Y 
M19 Myeloma M 62 1 1 2 Y 
M20 Myeloma F 74 7 5 12 Y 
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1Age at interview; 2T1: Initial symptom/health change (estimated from information in the routine self-reported HMRN questionnaire) to 
first help seeking (appraisal and help-seeking interval); 3T2: First help-seeking to diagnosis (diagnostic interval): 4T3: Initial symptom/health 
change to diagnosis (total interval); 5Lymphoma patient ID 01; 6Myeloma patient ID 01.  
 
 
